Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rucaparib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 20/20 | 1.00 |
| ▸ | PARP2 known ✓ | Q9UGN5 | 9/20 | 0.90 |
| ▸ | PARP3 known ✓ | Q9Y6F1 | 1/20 | 0.90 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.90 |
| ▸ | TNKS | O95271 | 1/20 | 0.90 |
| ▸ | PGR | P06401 | 1/20 | 0.90 |
| ▸ | CDK1 | P06493 | 1/20 | 0.90 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.90 |
| ▸ | POLA1 | P09884 | 1/20 | 0.90 |
| ▸ | PIM1 | P11309 | 1/20 | 0.90 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.90 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.90 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.90 |
| ▸ | CDK16 | Q00536 | 1/20 | 0.90 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.90 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.90 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.90 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.90 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.90 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rucaparib SCHEMBL844872 | 1.00 | PARP1 (1.00) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL29351768 | 0.95 | PARP1 (1.00) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL844585 | 0.95 | PARP1 (1.00) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL29392034 | 0.94 | PARP1 (0.98) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL5746065 | 0.94 | PARP1 (0.98) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL5747917 | 0.92 | PARP1 (0.90) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL30413070 | 0.91 | PARP1 (0.87) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL6702365 | 0.89 | PARP1 (0.84) | PARP1PARP2DYRK3TNKSPGR | |
| SCHEMBL25150522 | 0.85 | PARP1 (0.81) | PARP1PARP2DYRK3TNKSPGR | |
| Phosphoric Acid SCHEMBL21122083 | 0.85 | PARP1 (0.74) | PARP1PARP2DYRK3TNKSPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187698-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2025-01-07 | — | — | US | claimed |
| EP-4419094-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | Edison Oncology (US) | 2024-08-28 | — | — | EP | claimed |
| EP-4319729-A1 | CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS | Cardiff Oncology, Inc. (US) | 2024-02-14 | — | — | EP | claimed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | claimed |
| US-20220324832-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-13 | — | — | US | claimed |
| WO-2022217060-A1 | CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS | CARDIFF ONCOLOGY, INC. (US) | 2022-10-13 | — | — | WO | claimed |
| US-12631620-B2 | Methods of generating organoids for high throughput screening of drugs | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2026-05-19 | — | — | US | disclosed |
| US-20260115285-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | TORAY INDUSTRIES, INC. (JP) | 2026-04-30 | — | — | US | disclosed |
| US-20260083724-A1 | COMPOUNDS TARGETING PAX3::FOXO1 FUSION PROTEIN | GEORGETOWN UNIVERSITY (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260000714-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12485088-B2 | Rapidly-orodispersible tablets having an interior cavity | Aprecia Pharmaceuticals LLC (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4653054-A2 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | Biomed Valley Discoveries, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12472261-B2 | Conjugated inhibitors of DNA damage response | PROLYNX LLC (US) | 2025-11-18 | — | — | US | disclosed |
| WO-2022060477-A1 | METHODS FOR TREATING CANCERS WITH INHIBITORS TARGETING THE ROLE OF GRB2 IN DNA REPAIR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-03-24 | — | — | WO | disclosed |
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | Triastek, Inc. (CN) | 2022-03-22 | — | — | US | disclosed |
| EP-3966782-A2 | METHODS FOR CHARACTERIZING AND TREATING A CANCER TYPE USING CANCER IMAGES | Tesaro, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20220054409-A1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC | 2022-02-24 | — | — | US | disclosed |
| US-20220042975-A1 | METHODS OF GENERATING ORGANOIDS FOR HIGH THROUGHPUT SCREENING OF DRUGS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-02-10 | — | — | US | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115285-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | PARP11, PARP1, PARP14 | PARP1 2/4885PARP2 5/4885PARP3 10/4885 |
| US-20220324832-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | PARP1 3696/4885PARP2 2408/4885PARP3 4075/4885 |
| US-12631620-B2 | Methods of generating organoids for high throughput screening of drugs | HGF, UGT1A10, TGFB2 | PARP1 1343/4885PARP2 248/4885PARP3 1547/4885 |
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | CYP2D6, CYP3A7, CYP3A5 | PARP1 4147/4885PARP2 4120/4885PARP3 3631/4885 |
| US-20260083724-A1 | COMPOUNDS TARGETING PAX3::FOXO1 FUSION PROTEIN | PAX3, FOXO1, PAXBP1 | PARP1 903/4885PARP2 1290/4885PARP3 2258/4885 |
| US-12187698-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | PARP1 3696/4885PARP2 2408/4885PARP3 4075/4885 |
| US-20260000714-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | KIT, CPA3, MKI67 | PARP1 3299/4885PARP2 2033/4885PARP3 1521/4885 |
| US-12472261-B2 | Conjugated inhibitors of DNA damage response | DCLRE1A, DDB1, RAD50 | PARP1 36/4885PARP2 35/4885PARP3 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.